Chinese Company Hua Medicine Reports Significant Revenue Growth
Hua Medicine, a leading Chinese biotechnology firm, announced a remarkable revenue growth of <strong>93%</strong> for 2026. In an exclusive interview with Bloomberg's 'China' program, Strategic Director George Lin discussed the prospects of the company's main drug, Duzaglitin, and plans for expansion into new markets.